individuals (Table 2) , such as those with chronic pancreatitis (CP), 9 cystic fibrosis (CF), 19 pancreatic cancer 20 and pancreas resection. 21 EPI may also coexist with gastrointestinal conditions, including IBD, coeliac disease or IBS (Table 2) . [22] [23] [24] EPI may be particularly common whenever diarrhoea is present, whether with IBS (6%) 22 or coeliac disease despite adopting a gluten-free diet (30%). 25 The prevalence
of EPI also appears to increase with age. 26, 27 EPI may also occur in individuals with rare genetic diseases such as Shwachman-Diamond syndrome 28 and Johanson-Blizzard syndrome.
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| Aetiology and pathology of exocrine pancreatic insufficiency
Most commonly, EPI stems from partial or total loss of pancreatic parenchyma because of CP, CF or pancreatic resection, 6 ,7 although many other aetiologies are possible ( Figure 1 ). Physical obstruction of the pancreatic duct, as might be caused by a pancreatic tumour, can also result in EPI. 20 Secretion of pancreatic enzymes may be impaired because of reduced neurohormonal stimulation (eg, in coeliac disease). 14, 30, 31 Pancreatic enzymes may be inactivated by overproduction of gastric acid in Zollinger-Ellison syndrome 6 or when acidic gastric chyme is inadequately neutralised if the pancreas does not appropriately produce or release bicarbonate. 7 Mixing of gastric chyme with pancreatic enzymes in the duodenum can be rendered ineffective when anatomy is altered (eg, after gastric bypass surgery) 7 or when the digestive process is unco-ordinated, resulting in postprandial dyskinesia. Less obvious conditions, such as oesophagectomy, 32 IBS, 22 type 1 diabetes, 33, 34 and type 3c ("pancreatogenic") diabetes secondary to CP or pancreatic cancer have also been associated with the development of exocrine dysfunction. 35, 36 Diabetes may eventually lead to pancreatic dysfunction because of damage from microvascular pathology.
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| Importance of diagnosing exocrine pancreatic insufficiency
Symptoms and severity of EPI can vary widely from patient to patient. 9 The typical symptoms of EPI (eg, bloating, abdominal discomfort, steatorrhoea, diarrhoea, excess flatulence, weight loss) are often found with other gastrointestinal conditions (Table 1) . Thus, EPI may be missed in the differential diagnosis except in patients with "known"
conditions that predispose to EPI, such as CP, 39 CF, 40 pancreatic resection 21 or pancreatic cancer. 20 This is unfortunate because delayed diagnosis of EPI may result in deleterious effects (Table 3) . Furthermore, an underlying condition such as CP or a pancreatic malignancy may go unrecognised, with potentially significant long-term consequences.
In individuals with EPI, clinically relevant maldigestion may occur earlier than overt symptoms (Table 3) T A B L E 1 Common symptoms shared by EPI and other gastrointestinal conditions 3, 6, [8] [9] [10] [11] [12] [13] 15 concentrations of vitamin E can cause neurological difficulties such as ataxia and peripheral neuropathy. 5 A deficiency in vitamin K can lead to a higher risk of haemorrhage, which may manifest as ecchymoses. 5 In children with CF, malabsorption of proteins and fat caused by untreated EPI is associated with poor growth. 44 In adults with pancreatic diseases, EPI is strongly associated (P < .001) with muscle wasting. 45 These consequences of EPI-related malnutrition can be further compounded if patients consciously choose to avoid certain foods, such as fatty items, that are likely to produce troublesome symptoms. 46 Exocrine pancreatic insufficiency is one of the factors that contributes to the malnutrition that is commonly present in patients with pancreatic cancer (Table 3) . 47 In one postoperative study, most patients with partial resection of the pancreas because of pancreatic cancer developed EPI at the earliest assessment (6 weeks), and a majority of patients continued to have EPI at months 3, 6 and 12. 48 Malnutrition is a predictor of poor outcomes following surgery for pancreatic cancer. 47 In an analysis of patients undergoing pancreatic resection for pancreatic cancer, patients at high risk for malnutrition had a fivefold higher surgical-site infection rate, a fourfold longer hospital stay and a higher overall morbidity rate than patients at low risk for malnutrition. 49 Severe weight loss (ie, >8.4% of preoperative body mass) after resection of pancreatic cancer has been associated with significantly higher mortality compared with mild weight loss. 50 In an analysis of patients with advanced pancreatic cancer, more severe EPI was significantly associated with decreased survival. 51 Conversely, in a different analysis, nutritional support was significantly and independently associated with longer survival in patients with pancreatic cancer, 63% of whom had symptomatic EPI.
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Malnutrition caused by EPI may also develop in patients with CP (Table 3) . 53 Patients with CP have increased risks of osteoporosis 54 and mortality 55 
| Patient historical factors
The importance of a careful past medical, surgical, family and social history is paramount to elucidate the symptoms and guide investigations of potential EPI aetiologies and targets for therapy. When a patient presents with a history of persistent bloating, diarrhoea, fatty food intolerance and abdominal pain, suspicion of EPI ranks high among several possible diagnoses. A history of alcohol abuse and smoking may predispose to the gradual development of CP with associated EPI. 57 Smoking is consistent with an increased likelihood of CP, pancreatic cancer and EPI; age may also increase the risk of EPI (≥60 years in a large association study of the general population in Germany). 27 Steady weight loss could be consistent with maldigestion and malabsorption. 46 However, because EPI can occur at any stage of life, it is possible that younger individuals and even those who are overweight or obese may develop EPI. A history of chronic alcohol and tobacco abuse should raise the possibility of underlying malignancy, particularly pancreatic cancer. 
| Laboratory tests for diagnosis of exocrine pancreatic insufficiency
Traditionally, some clinicians may order testing for the presence of faecal fat. 59 However, the absence of steatorrhoea is not unusual because even residual endogenous lipase production is sufficient to mask this symptom, or the patient may be avoiding fatty food because it provokes gastrointestinal symptoms. 9, 44 The presence of gross steatorrhoea or positive qualitative faecal fat testing, although helpful for supporting the diagnosis of EPI, is not sensitive or specific for EPI. 6, 14, 60 A quantitative determination of faecal fat is informative but requires the patient to eat a high-fat diet for 5 days or longer and collect all stool for the last 72 hours of the dietary regimen. 9,61 Inspection of stool for fat droplets is much simpler in all respects but provides only qualitative results that are subject to various interpretations. 5, 9, 61 Neither kind of faecal fat determination is specific for EPI because other conditions can produce the same findings. 9 Direct tests of pancreatic function based on stimulation of excretions by secretin and cholecystokinin have excellent performance but are conducted only in specialty centres, are invasive, and require a complicated procedure (even with the advent of endoscopy-based techniques) performed by skilled staff.
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More recently, FE-1 testing has been considered for evaluation of EPI. FE-1 is an enzyme produced and released by the pancreas and remains intact during intestinal transit. 6 It is highly sensitive and specific for detecting advanced EPI but is less reliable in milder cases of EPI, in patients following pancreatic resection, or in patients with watery diarrhoea. 6, 14, 60 The patient should be counselled on proper collection of the sample to avoid spurious results (eg, because of sample dilution with diarrhoea), although this might not be critical, 62 and the testing laboratory can remove excess water via centrifugation or lyophilisation. 9, 63 Faecal chymotrypsin should not be used as a diagnostic test for EPI because it is less sensitive than FE-1.
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| Treatment and management of exocrine pancreatic insufficiency
The main goals of treatment of EPI are to relieve gastrointestinal symptoms and correct or improve the nutritional status of the patient. 39 Because of the diverse causes and differing degrees of severity of EPI, treatment is highly individualised and often semi-empirical. Multiple professional guidelines and recommendations have addressed this topic, 5, 15, 44, 64, 65 and several have been conveniently summarised. 66 Certainly, patients with EPI who smoke or abuse alcohol should be counselled to quit. 15 PERT is a cornerstone of the management of EPI;
treatment is administered orally with meals and snacks at dosages that are adjusted to meet therapeutic goals. 66 The success of a regimen is usually judged on the basis of achieving good nutritional outcomes while resolving any symptoms. Testing and treatment for presence of diabetes type 3c and impaired glucose tolerance should be performed, given the increased risk of pancreatic endocrine dysfunction when pancreatic disease is present. 67 
| CONCLUSIONS
In summary, EPI is a frequent source of malabsorption that presents as a syndrome characterised by broad symptoms of abdominal discomfort, bloating, flatulence, diarrhoea, weight loss and steatorrhoea (Table 4) . These non-specific symptoms confound differential diagnosis because they overlap with those of several other 
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